William G. Cance
Affiliations: | Biophysics | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
General Biophysics, BiochemistryGoogle:
"William Cance"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Stahl E, Nott R, Koessel K, et al. (2020) Computational-based discovery of FAK FERM domain chemical probes that inhibit HER2-FAK cancer signaling. Chemical Biology & Drug Design. 95: 584-599 |
| Marlowe T, Alvarado C, Rivera A, et al. (2019) Development of a High-Throughput Fluorescence Polarization Assay to Detect Inhibitors of the FAK-Paxillin Interaction. Slas Discovery : Advancing Life Sciences R & D. 2472555219874313 |
| Marlowe T, Dementiev A, Figel S, et al. (2019) High resolution crystal structure of the FAK FERM domain reveals new insights on the Druggability of tyrosine 397 and the Src SH3 binding site. Bmc Molecular and Cell Biology. 20: 10 |
| Lenzo FL, Cance WG. (2017) From tumorigenesis to microenvironment and immunoregulation: the many faces of focal adhesion kinase and challenges associated with targeting this elusive protein. Translational Cancer Research. 6: S957-S960 |
| Marlowe TA, Lenzo FL, Figel SA, et al. (2016) Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-kinase Inhibitors. Molecular Cancer Therapeutics |
| Zhang H, Shao H, Golubovskaya VM, et al. (2016) Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways. British Journal of Cancer |
| Wilton J, Kurenova E, Pitzonka L, et al. (2016) Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. European Journal of Drug Metabolism and Pharmacokinetics. 41: 55-67 |
| Li Z, Lebedyeva IO, Golubovskaya VM, et al. (2015) Synthesis and bioactivity of a Goralatide analog with antileukemic activity. Bioorganic & Medicinal Chemistry. 23: 5056-60 |
| Golubovskaya V, O'Brien S, Ho B, et al. (2015) Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15. Journal of Cancer Research and Clinical Oncology |
| Golubovskaya V, Curtin L, Groman A, et al. (2015) In vivo toxicity, metabolism and pharmacokinetic properties of FAK inhibitor 14 or Y15 (1, 2, 4, 5-benzenetetramine tetrahydrochloride). Archives of Toxicology. 89: 1095-101 |